Tigermed

LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.

Beino Bio is a China-based supplier of biopharmaceutical CDMO and cell culture media, providing process development and GMP production services for companies interested in introducing protein, cell therapy and gene therapy drugs to the Chinese and global markets.

Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development.

CytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline.

Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates in development.

Gmax Biopharm develops GPCR antibody therapeutics for unmet medical needs in cardiovascular diseases, metabolic disorders, and cancer. Gmax Biopharm develops a proprietary platform with a systemic approach to GPCR MAb generation, screening, and development. Gmax Biopharm enables antibody screening, humanization, and engineering to produce antibody candidates with high drugability and developability.

3D Medicines, we use individual’s genetic information to prevent, diagnose, and treat cancer. We develop personalized medicines according to target population’s genetic background, to increase efficacy and safety.

Hinova Pharma is an innovative drug research and development manufacturer that provides users with compound HC-1119 androgen receptor (AR) antagonism by using drug discovery systems such as medicinal chemistry, biological screening, process research, quality research, clinical reporting, and clinical research. Drugs, HC-1102 androgen receptor inhibitors and other products, for the treatment of advanced prostate cancer and breast cancer.

Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates in development.

Asieris Pharmaceuticals is a Chinese biotech company focusing on therapeutic areas in oncology and multidrug-resistant infections.

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.

EOC Pharma is an integrated biopharmaceutical company that is focused on the manufacturing, development and commercialization of innovative global oncology products in China. They have adopted a licensing model in order to build EOC’s innovative pipeline by plugging their partner’s molecule into EOC’s “core engine” of local manufacturing, clinical development, regulatory filing, and commercialization. The company has a pipeline of seven novel products from global biopharmaceutical partners that are potentially first- and best-in-class. Until now, EOC has obtained four Class I innovative drug CTA approvals and initiated clinical studies of four lead products in China.,EOC has a team of entrepreneurs and consultants with overseas background that boasts of first-class pharmaceutical R&D expertise as well as rich industry experience. The company owns an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City and has offices in Shanghai, Beijing, Hong Kong and Los Angeles. EOC will leverage forward-looking licensing which will provide product opportunities to their integrated platform, generating a highly strategic portfolio. Ultimately, this will position EOC at the top of oncology innovation in China.

Yaxincheng provides medical device and pharmaceutical translation services for the life sciences industry. They provide translation language pairs, including chinese, english, french, german, japanese, korean, spanish and so on.

CMAB BioPharm is a Biopharmaceutical Service Firm. Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.

Collietech is a Chinese electronic common technical document (eCTD) software and service provider, focusing on information technology in life science field.

MED.CIRCLE is a medical information service company. It is a service platform that can support many medical academic activities. Their services include medical academic activities and medical device innovation incubation.

Yaxincheng provides medical device and pharmaceutical translation services for the life sciences industry. They provide translation language pairs, including chinese, english, french, german, japanese, korean, spanish and so on.

NovaSignal is a medical technology company commercializing a robotic cerebral ultrasound system. Robotic System combines non-invasive ultrasound, robotics, and artificial intelligence to assess real-time cerebral blood flow.

Dream CIS pharmaceutical companies, bio ventures, medical device companies, health functional trial consignment agencies that provide services related to clinical trials for food companies: (CRO Contract The Research Organization). The main service area associated with drug development and clinical trials Dream CIS provides the 'drug and medical device clinical trial (Clinical Research)', 'post-marketing research (PV & PMS)', 'Data Management', 'Statistical Analysis' 'Contract Audit', 'human body test of functional foods', and 'professional workforce training'. Dream C-AS meets the needs of customers through scientific and systematic quality control activities, and is committed to grow with customers based on a thorough ethical awareness.

Yijiayi have treatment methods for cancer patients such as surgery, radiotherapy, and chemotherapy can result in toxic and side effects such as dry mouth, nausea and vomiting, diarrhea, and constipation, as psychological factors such as depression and anxiety, which can affect the patient's appetite and eating habits of nutritional deficiencies in cancer patients.

Frontage Laboratories is a Contract Research Organization (CRO) that provides integrated, science-driven, product development services. Frontage helps biopharmaceutical organizations advance their research and development efforts with full-service offerings– including bioanalysis, preclinical and clinical studies, analytical testing, and product development support– spanning discovery stages through late-stage clinical trials. The company also provides turnkey product development, bioequivalence, and analytical services to generic and consumer health pharmaceutical companies to support abbreviated new drug applications and 505.b.2 application submissions.